NASH (Non-alcoholic Steatohepatitis) biomarkers - Global Market Outlook (2017-2023)

  • ID: 4426453
  • Report
  • Region: Global
  • 185 pages
  • Stratistics Market Research Consulting Pvt Ltd
UP TO OFF
until Jan 31st 2019
10% Free customization

This report comes with 10% free customization, enabling you to add data that meets your specific business needs.

1 of 4

FEATURED COMPANIES

  • Allergan Plc
  • AstraZeneca
  • Boehringer Ingelheim
  • Enzo Biochem
  • GENFIT SA
  • Intercept Ph
  • MORE
The Global NASH (Non-Alcoholic Steatohepatitis) Biomarkers market is expected to grow from $202.12 million in 2016 to reach $1,350.23 million by 2023 with a CAGR of 31.2%. Rising demand for noninvasive diagnostic tools matched with growing levels of patient awareness is likely to augment the growth of NASH biomarkers market over the forecast period. Furthermore, growing prevalence of chronic liver conditions is expected to upsurge demand for noninvasive diagnostic tools. On the contrary, huge price and invasiveness, ensued in changing the taste for noninvasive biomarkers is expected to limit the market growth over the forecast period.

Biomarkers are commonly proteins detected in the blood, urine or other body fluids that are either raised by the tumor itself. Serum Biomarker should be measured at a low cost, by a widely usable assay with reproducible outcomes in a specimen that is comfortable to access. The serum biomarkers have the ability to deliver efficient results. Apoptosis markers follow this lead closely. Hospitals and diagnostic laboratories are likely to be rising in requirement for non-invasive NASH diagnostic and monitoring instruments at the ongoing tests by pharmaceutical manufacturers and CRO.

North America holds the largest market share due to different reasons like rising prevalence of infectious diseases, cardiovascular diseases & cancer, rising R&D activities from key players, and favorable government initiatives. Asia Pacific is expected to become the fastest growing market owing to enlargement of key market participants. There is a substantial rise in R&D spending for biomarkers from the countries like China, India and Japan. In addition, increasing demand for biomarkers among end-users and rising number of CROs are factors favoring the market growth in this region.

Some of the key players in global NASH (Non-Alcoholic Steatohepatitis) Biomarkers market include Allergan Plc, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb Company, Dainippon Sumitom-Pharma (DSP), Enz-Biochem, GENFIT SA, Gilead Sciences, Inc. (GILD), Intercept Pharmaceuticals, Novartis AG, Nov-Nordisk A/S, Pfizer Inc, Prometheus Laboratories Corp, Raptor Pharmaceutical Corp and Siemens Heathcare Pvt. Ltd.

Types Covered:
  • Hepatic fibrosis biomarkers
  • Serum biomarkers
  • Oxidative stress biomarkers
  • Apoptosis biomarkers
  • Other Biomarkers Types
Application Types Covered:
  • Hospitals
  • Pharma & CR-Industry
  • Academic Research Institutes
  • Diagnostic Labs
Regions Covered:
  • North America
  • US
  • Canada
  • Mexico
  • Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
  • Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • Rest of Asia Pacific
  • South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
  • Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa
What The Report Offers:
  • Market share assessments for the regional and country level segments
  • Market share analysis of the top industry players
  • Strategic recommendations for the new entrants
  • Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Allergan Plc
  • AstraZeneca
  • Boehringer Ingelheim
  • Enzo Biochem
  • GENFIT SA
  • Intercept Ph
  • MORE
1. Executive Summary

2. Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions

3. Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 End User Analysis
3.7 Emerging Markets
3.8 Futuristic Market Scenario

4. Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry

5. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market, By Type
5.1 Introduction
5.2 Hepatic fibrosis biomarkers
5.3 Serum biomarkers
5.4 Oxidative stress biomarkers
5.5 Apoptosis biomarkers
5.5 Other Biomarkers Types

6. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market, By End-user
6.1 Introduction
6.2 Hospitals
6.3 Pharma & CRO Industry
6.4 Academic Research Institutes
6.5 Diagnostic Labs

7. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market, By Geography
7.1 Introduction
7.2 North America
7.2.1 US
7.2.2 Canada
7.2.3 Mexico
7.3 Europe
7.3.1 Germany
7.3.2 U.K
7.3.3 France
7.3.4 Italy
7.3.5 Spain
7.3.6 Rest of Europe
7.4 Asia Pacific
7.4.1 Japan
7.4.2 China
7.4.3 India
7.4.4 Australia
7.4.5 New Zealand
7.4.6 South Korea
7.4.7 Rest of Asia Pacific
7.5 South America
7.5.1 Argentina
7.5.2 Brazil
7.5.3 Chile
7.5.4 Rest of South America
7.6 Middle East & Africa
7.6.1 Saudi Arabia
7.6.2 UAE
7.6.3 Qatar
7.6.4 South Africa
7.6.5 Rest of Global

8. Key Developments
8.1 Agreements, Partnerships, Collaborations and Joint Ventures
8.2 Acquisitions & Mergers
8.3 New Product Launch
8.4 Expansions
8.5 Other Key Strategies

9. Company Profiling
9.1 Allergan Plc
9.2 AstraZeneca
9.3 Boehringer Ingelheim
9.4 Bristol-Myers Squibb Company
9.5 Dainippon Sumitomo Pharma (DSP)
9.6 Enzo Biochem
9.7 GENFIT SA
9.8 Gilead Sciences, Inc. (GILD)
9.9 Intercept Pharmaceuticals
9.10 Novartis AG
9.11 Novo Nordisk A/S
9.12 Pfizer Inc
9.13 Prometheus Laboratories Corp
9.14 Raptor Pharmaceutical Corp
9.15 Siemens Heathcare Pvt. Ltd.

List of Tables

Table 1 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By Region (2014-2023) ($MN)
Table 2 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By Type (2014-2023) ($MN)
Table 3 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By Hepatic fibrosis biomarkers (2014-2023) ($MN)
Table 4 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By Serum biomarkers (2014-2023) ($MN)
Table 5 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By Oxidative stress biomarkers (2014-2023) ($MN)
Table 6 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By Apoptosis biomarkers (2014-2023) ($MN)
Table 7 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By Other Biomarkers Types (2014-2023) ($MN)
Table 8 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By End-user (2014-2023) ($MN)
Table 9 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By Hospitals (2014-2023) ($MN)
Table 10 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By Pharma & CRO Industry (2014-2023) ($MN)
Table 11 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By Academic Research Institutes (2014-2023) ($MN)
Table 12 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By Diagnostic Labs (2014-2023) ($MN)
Table 13 North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By Country (2014-2023) ($MN)
Table 14 North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By Type (2014-2023) ($MN)
Table 15 North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By Hepatic fibrosis biomarkers (2014-2023) ($MN)
Table 16 North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By Serum biomarkers (2014-2023) ($MN)
Table 17 North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By Oxidative stress biomarkers (2014-2023) ($MN)
Table 18 North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By Apoptosis biomarkers (2014-2023) ($MN)
Table 19 North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By Other Biomarkers Types (2014-2023) ($MN)
Table 20 North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By End-user (2014-2023) ($MN)
Table 21 North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By Hospitals (2014-2023) ($MN)
Table 22 North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By Pharma & CRO Industry (2014-2023) ($MN)
Table 23 North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By Academic Research Institutes (2014-2023) ($MN)
Table 24 North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By Diagnostic Labs (2014-2023) ($MN)
Table 25 Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By Country (2014-2023) ($MN)
Table 26 Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By Type (2014-2023) ($MN)
Table 27 Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By Hepatic fibrosis biomarkers (2014-2023) ($MN)
Table 28 Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By Serum biomarkers (2014-2023) ($MN)
Table 29 Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By Oxidative stress biomarkers (2014-2023) ($MN)
Table 30 Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By Apoptosis biomarkers (2014-2023) ($MN)
Table 31 Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By Other Biomarkers Types (2014-2023) ($MN)
Table 32 Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By End-user (2014-2023) ($MN)
Table 33 Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By Hospitals (2014-2023) ($MN)
Table 34 Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By Pharma & CRO Industry (2014-2023) ($MN)
Table 35 Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By Academic Research Institutes (2014-2023) ($MN)
Table 36 Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By Diagnostic Labs (2014-2023) ($MN)
Table 37 Asia Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By Country (2014-2023) ($MN)
Table 38 Asia Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By Type (2014-2023) ($MN)
Table 39 Asia Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By Hepatic fibrosis biomarkers (2014-2023) ($MN)
Table 40 Asia Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By Serum biomarkers (2014-2023) ($MN)
Table 41 Asia Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By Oxidative stress biomarkers (2014-2023) ($MN)
Table 42 Asia Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By Apoptosis biomarkers (2014-2023) ($MN)
Table 43 Asia Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By Other Biomarkers Types (2014-2023) ($MN)
Table 44 Asia Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By End-user (2014-2023) ($MN)
Table 45 Asia Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By Hospitals (2014-2023) ($MN)
Table 46 Asia Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By Pharma & CRO Industry (2014-2023) ($MN)
Table 47 Asia Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By Academic Research Institutes (2014-2023) ($MN)
Table 48 Asia Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By Diagnostic Labs (2014-2023) ($MN)
Table 49 South America NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By Country (2014-2023) ($MN)
Table 50 South America NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By Type (2014-2023) ($MN)
Table 51 South America NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By Hepatic fibrosis biomarkers (2014-2023) ($MN)
Table 52 South America NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By Serum biomarkers (2014-2023) ($MN)
Table 53 South America NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By Oxidative stress biomarkers (2014-2023) ($MN)
Table 54 South America NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By Apoptosis biomarkers (2014-2023) ($MN)
Table 55 South America NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By Other Biomarkers Types (2014-2023) ($MN)
Table 56 South America NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By End-user (2014-2023) ($MN)
Table 57 South America NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By Hospitals (2014-2023) ($MN)
Table 58 South America NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By Pharma & CRO Industry (2014-2023) ($MN)
Table 59 South America NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By Academic Research Institutes (2014-2023) ($MN)
Table 60 South America NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By Diagnostic Labs (2014-2023) ($MN)
Table 61 Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By Country (2014-2023) ($MN)
Table 62 Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By Type (2014-2023) ($MN)
Table 63 Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By Hepatic fibrosis biomarkers (2014-2023) ($MN)
Table 64 Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By Serum biomarkers (2014-2023) ($MN)
Table 65 Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By Oxidative stress biomarkers (2014-2023) ($MN)
Table 66 Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By Apoptosis biomarkers (2014-2023) ($MN)
Table 67 Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By Other Biomarkers Types (2014-2023) ($MN)
Table 68 Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By End-user (2014-2023) ($MN)
Table 69 Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By Hospitals (2014-2023) ($MN)
Table 70 Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By Pharma & CRO Industry (2014-2023) ($MN)
Table 71 Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By Academic Research Institutes (2014-2023) ($MN)
Table 72 Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By Diagnostic Labs (2014-2023) ($MN)
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Allergan Plc
  • AstraZeneca
  • Boehringer Ingelheim
  • Bristol-Myers Squibb Company
  • Dainippon Sumitomo Pharma (DSP)
  • Enzo Biochem
  • GENFIT SA
  • Gilead Sciences, Inc. (GILD)
  • Intercept Ph
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll